{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T20:46:09Z","timestamp":1789159569580,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological and Toxicological Methods"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.vascn.2025.108389","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T20:06:33Z","timestamp":1754424393000},"page":"108389","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Therapeutic drug monitoring of busulfan and cyclophosphamide in hematologic malignancies: An LC-MS\/MS development, validation and application"],"prefix":"10.1016","volume":"135","author":[{"given":"Jinxingyi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruyu","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanshuai","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiejie","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vascn.2025.108389_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.114216","article-title":"Fast and reliable quantification of busulfan in blood plasma using two-channel liquid chromatography tandem mass spectrometry: Validation of assay performance in the presence of drug formulation excipients","volume":"203","author":"Andersen","year":"2021","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"10.1016\/j.vascn.2025.108389_bb0010","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jchromb.2014.09.008","article-title":"Analysis of cyclophosphamide and carboxyethylphosphoramide mustard enantiomers in human plasma and application to clinical pharmacokinetics","volume":"971","author":"Attie de Castro","year":"2014","journal-title":"Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences"},{"key":"10.1016\/j.vascn.2025.108389_bb0015","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/j.jchromb.2009.04.025","article-title":"Simultaneous determination of cyclophosphamide and carboxyethylphosphoramide mustard in human plasma using online extraction and electrospray tandem mass spectrometry (HTLC-ESI-MS\/MS)","volume":"877","author":"Bai","year":"2009","journal-title":"Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences"},{"key":"10.1016\/j.vascn.2025.108389_bb0020","series-title":"CYTOXAN (Cyclophosphamide)","author":"Baxter","year":"2013"},{"key":"10.1016\/j.vascn.2025.108389_bb0025","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/bmt.2015.238","article-title":"Busulfan fludarabine vs busulfan cyclophosphamide as a preparative regimen before allogeneic hematopoietic cell transplantation: Systematic review and meta-analysis","volume":"51","author":"Ben-Barouch","year":"2016","journal-title":"Bone Marrow Transplantation"},{"key":"10.1016\/j.vascn.2025.108389_bb0030","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15041283","article-title":"Precision oncology by point-of-care therapeutic drug monitoring and dosage adjustment of conventional cytotoxic chemotherapies: A perspective","volume":"15","author":"Briki","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.vascn.2025.108389_bb0035","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1039\/C9AN00576E","article-title":"A high-specificity immunoassay for the therapeutic drug monitoring of cyclophosphamide","volume":"144","author":"Broto","year":"2019","journal-title":"Analyst"},{"key":"10.1016\/j.vascn.2025.108389_bb0040","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1016\/j.jchromb.2010.10.003","article-title":"A fast and simple assay for busulfan in serum or plasma by liquid chromatography-tandem mass spectrometry using turbulent flow online extraction technology","volume":"878","author":"Bunch","year":"2010","journal-title":"Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences"},{"key":"10.1016\/j.vascn.2025.108389_bb0045","series-title":"9012 guidelines for validation of quantitative analytical method of biological samples","author":"Commission, C. P","year":"2015"},{"key":"10.1016\/j.vascn.2025.108389_bb0050","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jchromb.2007.04.024","article-title":"Simultaneous quantification of cyclophosphamide and its active metabolite 4-hydroxycyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (LC-MS\/MS)","volume":"854","author":"Ekhart","year":"2007","journal-title":"Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences"},{"key":"10.1016\/j.vascn.2025.108389_bb0055","series-title":"MYLERAN (Busulfan)","author":"GlaxoSmithKline","year":"2003"},{"key":"10.1016\/j.vascn.2025.108389_bb0060","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jchromb.2018.04.016","article-title":"A sensitive and rapid ultra high-performance liquid chromatography with tandem mass spectrometric assay for the simultaneous quantitation of cyclophosphamide and the 4-hydroxycyclophosphamide metabolite in human plasma","volume":"1086","author":"Hall","year":"2018","journal-title":"Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences"},{"key":"10.1016\/j.vascn.2025.108389_bb0065","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1365-2125.2012.04223.x","article-title":"Cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitis","volume":"74","author":"Joy","year":"2012","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"5","key":"10.1016\/j.vascn.2025.108389_bb0070","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/01.ftd.0000173372.04945.7b","article-title":"Tandem mass spectrometry method for the quantification of serum busulfan","volume":"27","author":"Kellogg","year":"2005","journal-title":"Therapeutic Drug Monitoring"},{"key":"10.1016\/j.vascn.2025.108389_bb0075","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40164-021-00240-3","article-title":"Roles of the intestinal microbiota and microbial metabolites in acute GVHD","volume":"10","author":"Lin","year":"2021","journal-title":"Experimental Hematology & Oncology"},{"key":"10.1016\/j.vascn.2025.108389_bb0080","doi-asserted-by":"crossref","first-page":"8913","DOI":"10.1038\/s41598-020-65919-9","article-title":"UPLC-tandem mass spectrometry for quantification of Busulfan in human plasma: Application to therapeutic drug monitoring","volume":"10","author":"Matar","year":"2020","journal-title":"Scientific Reports"},{"key":"10.1016\/j.vascn.2025.108389_bb0085","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1517\/17425250903107764","article-title":"Busulfan in hematopoietic stem cell transplant setting","volume":"5","author":"McCune","year":"2009","journal-title":"Expert Opinion on Drug Metabolism & Toxicology"},{"key":"10.1016\/j.vascn.2025.108389_bb0090","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3343\/alm.2014.34.1.7","article-title":"Quantification of human plasma-busulfan concentration by liquid chromatography-tandem mass spectrometry","volume":"34","author":"Moon","year":"2014","journal-title":"Annals of Laboratory Medicine"},{"key":"10.1016\/j.vascn.2025.108389_bb0095","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2165\/00003088-199120030-00002","article-title":"Clinical pharmacokinetics of cyclophosphamide","volume":"20","author":"Moore","year":"1991","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/j.vascn.2025.108389_bb0100","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/clinchem\/47.8.1437","article-title":"Sensitive and rapid quantification of busulfan in small plasma volumes by liquid chromatography-electrospray mass spectrometry","volume":"47","author":"Murdter","year":"2001","journal-title":"Clinical Chemistry"},{"key":"10.1016\/j.vascn.2025.108389_bb0105","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.bbmt.2016.07.013","article-title":"Personalizing Busulfan-based conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee","volume":"22","author":"Palmer","year":"2016","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"10.1016\/j.vascn.2025.108389_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2023.123754","article-title":"Simultaneous quantification of pirarubicin, doxorubicin, cyclophosphamide, and vincristine in human plasma of patients with non-Hodgkin's lymphoma by LC-MS\/MS method","volume":"1224","author":"Qi","year":"2023","journal-title":"Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences"},{"key":"10.1016\/j.vascn.2025.108389_bb0115","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2165\/00003088-200645030-00006","article-title":"Quantification of busulfan in saliva and plasma in haematopoietic stem cell transplantation in children\u202f: Validation of liquid chromatography tandem mass spectrometry method","volume":"45","author":"Rauh","year":"2006","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/j.vascn.2025.108389_bb0120","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0378-4347(01)00243-2","article-title":"Liquid chromatography-tandem mass spectrometric quantitation of cyclophosphamide and its hydroxy metabolite in plasma and tissue for determination of tissue distribution","volume":"759","author":"Sadagopa","year":"2001","journal-title":"Journal of Chromatography. B, Biomedical Sciences and Applications"},{"key":"10.1016\/j.vascn.2025.108389_bb0125","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1158\/1078-0432.CCR-05-2079","article-title":"Real-time dose adjustment of cyclophosphamide in a preparative regimen for hematopoietic cell transplant: A Bayesian pharmacokinetic approach","volume":"12","author":"Salinger","year":"2006","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.vascn.2025.108389_bb0130","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00277-020-04312-y","article-title":"Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: A prospective randomized trial","volume":"100","author":"Seydoux","year":"2021","journal-title":"Annals of Hematology"},{"key":"10.1016\/j.vascn.2025.108389_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2022.123228","article-title":"Cyclophosphamide, hydroxycyclophosphamide and carboxyethyl phosphoramide mustard quantification with liquid chromatography mass spectrometry in a single run human plasma samples: A rapid and sensitive method development","volume":"1198","author":"Shanker Kasudhan","year":"2022","journal-title":"Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences"},{"key":"10.1016\/j.vascn.2025.108389_bb0140","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1515\/CCLM.2011.710","volume":"49","author":"Shu","year":"2011","journal-title":"Clinical Chemistry and Laboratory Medicine"},{"key":"10.1016\/j.vascn.2025.108389_bb0145","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.826004","article-title":"Therapeutic drug monitoring of conditioning agents in pediatric allogeneic stem cell transplantation; where do we stand?","volume":"13","author":"van der Stoep","year":"2022","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.vascn.2025.108389_bb0150","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jchromb.2013.10.011","article-title":"A stable isotope-labeled internal standard is essential for correcting for the interindividual variability in the recovery of lapatinib from cancer patient plasma in quantitative LC-MS\/MS analysis","volume":"941","author":"Wu","year":"2013","journal-title":"Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences"},{"key":"10.1016\/j.vascn.2025.108389_bb0155","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.cca.2018.01.020","article-title":"A rapid and simple LC-MS\/MS method for personalized busulfan dosing in pediatric patients undergoing hematopoietic stem cell transplantation (HSCT)","volume":"479","author":"Xiao","year":"2018","journal-title":"Clinica Chimica Acta"}],"container-title":["Journal of Pharmacological and Toxicological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871925008093?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871925008093?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T11:07:13Z","timestamp":1772881633000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056871925008093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":31,"alternative-id":["S1056871925008093"],"URL":"https:\/\/doi.org\/10.1016\/j.vascn.2025.108389","relation":{},"ISSN":["1056-8719"],"issn-type":[{"value":"1056-8719","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic drug monitoring of busulfan and cyclophosphamide in hematologic malignancies: An LC-MS\/MS development, validation and application","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological and Toxicological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vascn.2025.108389","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108389"}}